• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Absci Corporation - Common Stock (NQ:ABSI)

    3.015 -0.145 (-4.59%)
    Streaming Delayed Price Updated: 11:35 AM EST, Jan 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Absci Corporation - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in Upcoming Investor Conferences
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
    Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs 
    From Absci Corporation; Oracle; AMD
    Via GlobeNewswire
    News headline image
    Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
    World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. 
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in Upcoming Investor Conferences
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Announces Pricing of Public Offering of Common Stock
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Announces Proposed Public Offering of Common Stock
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    iRhythm Technologies Announces Board Member Retirements and New Director Appointments
    From iRhythm
    Via GlobeNewswire
    News headline image
    Absci Appoints Biopharma Leader Mary Szela to Board of Directors
    Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise 
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in Upcoming Investor Conferences
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in Upcoming Investor Conferences
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in the TD Cowen 45th Annual Health Care Conference
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
    From Absci Corporation
    Via GlobeNewswire
    News headline image
    Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
    Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class... 
    From Absci Corporation; Owkin
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.